Search Results

You are looking at 91 - 100 of 744 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Robert J. Besaw, Adrienne R. Terra, Grace L. Malvar, Tobias R. Chapman, Lauren M. Hertan, and Benjamin L. Schlechter

UCOGC of the pancreas with a high tumor mutation burden (TMB) identified during next-generation sequencing (NGS). Third-line pembrolizumab monotherapy markedly reduced the primary pancreatic tumor and metastases in the lung and brain. Despite recent

Full access

Michael Karass, Rohan Bareja, Ethan Shelkey, Panagiotis J. Vlachostergios, Brian D. Robinson, Francesca Khani, Juan Miguel Mosquera, Douglas S. Scherr, Andrea Sboner, Scott T. Tagawa, Ana M. Molina, Olivier Elemento, David M. Nanus, and Bishoy M. Faltas

metastases were prospectively collected. Somatic DNA from tumor samples and germline DNA from peripheral blood mononuclear cells were submitted for WES as previously described. 3 RNA was extracted from tumor samples and submitted for RNA-seq. Whole

Full access

R. Michael Tuttle, Douglas W. Ball, David Byrd, Gilbert H. Daniels, Raza A. Dilawari, Gerard M. Doherty, Quan-Yang Duh, Hormoz Ehya, William B. Farrar, Robert I. Haddad, Fouad Kandeel, Richard T. Kloos, Peter Kopp, Dominick M. Lamonica, Thom R. Loree, William M. Lydiatt, Judith McCaffrey, John A. Olson Jr., Lee Parks, John A. Ridge, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, and Lori J. Wirth

aerodigestive tract compression or invasion are reported by up to 15% of patients with sporadic disease. 7 Symptoms from distant metastases in the lungs or bones occur in 5% to 10% of patients. The ability of the tumor to secrete measurable quantities of

Full access

Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold, and May T. Cho

treated initially with FOLFOX (5-FU/leucovorin/oxaliplatin). However, response imaging after 7 cycles showed progressive disease with new liver and lung metastases. He subsequently received 5 cycles of irinotecan and cetuximab but developed a small bowel

Full access

Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani

, including brain metastases, hemoptysis, or anticoagulation use. Survival Outcomes The primary outcome was OS, defined as the number of months from administration of first chemotherapy agent for metastatic disease until the date of death or end of the

Full access

Julie Hallet, Calvin Law, Simron Singh, Alyson Mahar, Sten Myrehaug, Victoria Zuk, Haoyu Zhao, Wing Chan, Angela Assal, and Natalie Coburn

gastric, small intestinal, colonic, and rectal. Metastatic disease was defined using ICD-9 and ICD-10 codes and divided into synchronous metastases (metastasis code ≤6 months from the date of NET diagnosis) and metachronous metastases (metastasis code >6

Full access

Puneeth Iyengar and Robert D. Timmerman

II NSCLC and isolated tumor metastases to the lungs, the standard approach to treatment has historically been surgical resection. For surgically resected stage I lesions, the 5-year overall survival (OS) rate is 60% to 70% in several series. 14 , 15

Full access

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

secondary local therapy may interrupt the natural history of disease and prevent progression to systemic disease. A basic question in this context is the extent to which this sequence of events—versus the presence of occult metastases at surgery

Full access

George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg

%) are less common primary sites. 14 A few GISTs occur within the abdomen and retroperitoneum but show no clear anatomic association with the GI tract. 15 Liver metastases and/or dissemination within the abdominal cavity are the usual clinical

Full access

Siddhartha Yadav, Sri Harsha Tella, Anuhya Kommalapati, Kristin Mara, Kritika Prasai, Mohamed Hamdy Mady, Mohamed Hassan, Rory L. Smoot, Sean P. Cleary, Mark J. Truty, Lewis R. Roberts, and Amit Mahipal

( Table 2 ). On MVA, age, ECOG performance status, presence of distant metastases, ALP level >200 U/L, and HgB level <9 g/dL were shown to determine median OS ( Table 3 ). Tumor size ≥5 cm was associated with an elevated hazard ratio (HR) of 1.24 compared